PARKINSON'S DISEASE NEWS

9th September 2009 - New research

THE EFFECT OF ROPINIROLE (REQUIP) ON PARKINSON'S DISEASE

Clinical neurology and neurosurgery [2009] Sep 2 [Epub ahead of print] (Valldeoriola F, Cobaleda S, Lahuerta J.) Complete abstract

Ropinirole is a dopamine agonist that is commonly used in the treatment of Parkinson's Disease. It is often sold as Requip, Ropark, or Adartrel. For more information go to Ropinirole. Ropinirole was found to be mostly used as an add on treatment (in 76% of cases), and as the only treatment in around a quarter (24%) of those people using it. The average maintenance dose was found to be 9mg per day, and normally be within the range 4mg to 15mg. Over a quarter (28%) of people taking Ropinirole reported adverse reactions. The most frequent adverse reactions were somnolence and sedation (9%), gastrointestinal symptoms (7%), increase in dyskinesia (6%), and orthostatic symptoms (4%). Treatment using Ropinirole was withdrawn in 14% of patients, largely because of either adverse reactions, lack of efficacy, or change in treatment. Over 80% of people taking Ropinirole were considered by their neurologists to have improved after taking it. For more current news go to Parkinson's Disease News.

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or new resources are added to Parkinson's Disease News,  please double click on  E-MAIL NOTIFICATION, or e-mail [email protected].  No form of identity is required.  E-mail addresses are not used for any other purpose.

Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of  all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided,  as well as links to the complete abstracts and news reports.